IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
IPO Detail
IPO Information
Financial
Financial Report
Peer Comparison
Peer Comparison
Performance
Performance Report
Bafna Pharmaceuticals IPO is a Fixed Price listing on BSE,NSE exchange, with an ipo size of ₹ 25.60 Cr. The company is based in Chennai and caters to Pharmaceutical sector. Keynote Financial Services , Ashika Capital are the merchant bankers of Bafna Pharmaceuticals IPO. It is a MainBoard IPO which filed its Draft Red Herring Prospectus (DRHP) on 27th December 2007.
Bafna Pharmaceuticals IPO posted revenues of ₹ 32.91 Cr. and PAT of ₹ 1.72 Cr. in FY08 on annualised basis.
Revenue:
₹ 32.91 Cr.
EBITDA Margin:
8.35
% 
Net Worth: ₹ 11.91 Cr.
Market Capitalisation:
[●]
P/E:
12.44 times
P/BV: [●]
EV/EBITDA: 8.28 times
Financial results of Bafna Pharmaceuticals IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | Dec-07 | FY07 | FY06 | FY05 | |
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 59.86 | 53.96 | 21.39 | 16.83 | |
| Net Worth | 11.91 | 9.09 | 5.61 | 4.23 | |
| Total Debt | 24.09 | 17.11 | 11.46 | 6.78 | |
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
24.68
32.91 |
38.61 | 21.36 | 26.62 | |
EBITDA
EBITDA on annualised basis |
2.06
2.75 |
1.19 | 1.06 | 1.39 | |
PAT
PAT on annualised basis |
1.29
1.72 |
0.97 | 0.85 | 0.89 | |
Bafna Pharmaceuticals IPO PAT Margin is 5.23 % , ROCE (Return on Capital Employed) is [●] % as per latest financial. The below table shows Bafna Pharmaceuticals IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | Dec-07 | FY07 | FY06 | FY05 |
|---|---|---|---|---|
| EBITDA Margin (%) | 8.35 | 3.08 | 4.96 | 5.22 |
| PAT Margin (%) | 5.23 | 2.51 | 3.98 | 3.34 |
| EPS (₹) | 1.35 | 2.51 | 2.19 | 3.89 |
| ROE (%) | 10.83 | 10.67 | 15.15 | 21.04 |
| ROCE (%) | [●] | [●] | [●] | [●] |
| ROA (%) | 2.16 | 1.80 | 3.97 | 5.29 |
| Debt to Equity | 2.02 | 1.88 | 2.04 | 1.60 |
The market Capitalisation of Bafna Pharmaceuticals IPO is ₹ 0.00 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Bafna Pharmaceuticals IPO prospectus highlights an Return on Equity (ROE) of 10.83 % , Return on Assets (ROA) of 2.16 %, and an EBITDA Margin of 8.35 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Bafna Pharmaceuticals IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Bafna Pharmaceuticals IPO is ₹ 0.00 Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Bafna Pharmaceuticals IPO has a Price-to-Earnings (PE) ratio of 12.44 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Bafna Pharmaceuticals IPO reported revenue of ₹ 17.28 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Bafna Pharmaceuticals IPO provide insights into sales growth, market demand, and business scalability.
Bafna Pharmaceuticals recorded an EBITDA of ₹ 2.75 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Bafna Pharmaceuticals Profit After Tax (PAT) is ₹ 1.72 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 32.91 Cr.
EBITDA Margin:
8.35
%
Net Worth: ₹ 11.91 Cr.
Market Capitalisation:
[●]
P/E:
12.44 times
P/BV: [●]
EV/EBITDA:
[●]
Bafna Pharmaceuticals operates in Pharmaceutical and Pharmaceutical. The Issue is listed on BSE,NSE in Jun, 2008. Bafna Pharmaceuticals IPO size was 25.60 with Issue price of 40.00 .
Merchant Banker(s) of Bafna Pharmaceuticals IPO: Keynote Financial Services Limited , Ashika Capital Limited
Bafna Pharmaceuticals IPO subscription was 0.00 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Bafna Pharmaceuticals IPO listed at a listing price of 38.50 against the offer price of 40.00.
The current market price of Bafna Pharmaceuticals is .
Why Us?
